OrthoPediatrics stock (US68735M1027): Pediatric orthopedic device maker trades near resistance

OrthoPediatrics Corp trades at $17.79 on Nasdaq with analyst consensus rating of Moderate Buy and $24.44 price target, representing 37.6% upside potential for the pediatric orthopedic medical device specialist.

OrthoPediatrics Corp, a medical device company focused exclusively on orthopedic solutions for children, is trading at $17.79 as of May 14, 2026, according to market data. The stock has shown modest movement year-to-date, up 0.2% from its January 1, 2026 opening price of $17.76. The company maintains a market capitalization of approximately $456.7 million on the Nasdaq exchange under ticker KIDS.

As of: May 14, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: OrthoPediatrics Corp
• Sector/industry: Medical Devices – Orthopedic Equipment
• Headquarters/country: Warsaw, Indiana, United States
• Core markets: Pediatric orthopedic solutions
• Key revenue drivers: Orthopedic medical devices for children
• Home exchange/listing venue: Nasdaq (KIDS)
• Trading currency: USD
• Market capitalization: $456.7 million
• Consensus analyst rating: Moderate Buy
• Consensus price target: $24.44

OrthoPediatrics Corp: core business model

OrthoPediatrics, founded in 2007 and headquartered in Warsaw, Indiana, operates as a specialized medical device manufacturer dedicated exclusively to pediatric orthopedic solutions. The company's focused business model targets the niche but critical market of orthopedic care for children, where specialized equipment and expertise differ significantly from adult orthopedic devices. With approximately 200 employees, the company serves hospitals, surgical centers, and orthopedic practices across the United States and international markets.

The company's specialization in pediatric orthopedics positions it within a defined market segment where competitors may lack dedicated product lines. This focused approach allows OrthoPediatrics to develop deep expertise in child-specific orthopedic challenges, including fracture management, deformity correction, and surgical instrumentation tailored to pediatric anatomy and physiology.

Main revenue and product drivers for OrthoPediatrics

OrthoPediatrics generates revenue through the sale of orthopedic medical devices specifically designed for pediatric patients. The company's product portfolio addresses various orthopedic conditions and surgical needs unique to children, including trauma care, deformity correction, and reconstructive procedures. Revenue is driven by adoption rates among pediatric orthopedic surgeons, hospital purchasing decisions, and the overall volume of pediatric orthopedic procedures performed in the United States and select international markets.

The pediatric orthopedic device market represents a specialized segment within the broader medical device industry. Growth drivers include increasing awareness of pediatric-specific orthopedic solutions, expansion of pediatric surgical capabilities at hospitals, and the company's ability to introduce new products and expand market penetration. The company's financial performance reflects both the size of its addressable market and its competitive positioning within the pediatric orthopedic device sector.

Analyst sentiment and valuation perspective

OrthoPediatrics has received a consensus analyst rating of Moderate Buy, based on 1 strong buy rating, 8 buy ratings, 1 hold rating, and 1 sell rating, according to available analyst data. The consensus price target of $24.44 represents approximately 37.6% upside potential from the current trading price of $17.79, suggesting analysts view the stock as undervalued relative to their forward expectations.

The company's current valuation metrics show a market capitalization of $456.7 million with 25.685 million shares outstanding. The stock's 52-week range extends from $14.42 to $23.70, indicating volatility within the pediatric medical device sector. Average daily trading volume stands at approximately 164,742 shares, providing reasonable liquidity for institutional and retail investors.

Why OrthoPediatrics matters for US investors

OrthoPediatrics represents a pure-play investment in the pediatric orthopedic medical device market, a specialized segment within the broader U.S. medical device industry. For U.S. investors seeking exposure to healthcare innovation focused on children's orthopedic care, the company offers a focused business model without diversification into adult orthopedics or other medical specialties. The company's Nasdaq listing and U.S. headquarters provide direct exposure to the American pediatric healthcare market, which represents a significant portion of global pediatric orthopedic device demand.

The company's market capitalization of approximately $457 million places it in the small-cap medical device category, offering potential growth opportunities for investors with higher risk tolerance. The analyst consensus of Moderate Buy and 37.6% upside to the price target suggest institutional research coverage views the company as having meaningful appreciation potential, though investors should conduct independent analysis before making investment decisions.

Conclusion

OrthoPediatrics Corp trades at $17.79 on Nasdaq with a Moderate Buy consensus rating and $24.44 price target, reflecting analyst expectations for the pediatric orthopedic device specialist. The company's focused business model, specialized market position, and analyst sentiment suggest ongoing interest from the investment community, though the stock's modest year-to-date performance reflects the broader market dynamics affecting medical device companies. Investors should monitor the company's quarterly financial results, product pipeline developments, and market adoption trends to assess the validity of analyst price targets and the company's competitive positioning within the pediatric orthopedic device sector.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.